$TBIO .51 x .53 Bottom Biotech DD Inside.
Post# of 26719
Stock Price History
Beta: 0.22
52-Week Change3: -67.53%
S&P500 52-Week Change3: -2.29%
52-Week High (May 29, 2015)3: 3.75
52-Week Low (Feb 23, 2016)3: 0.49
50-Day Moving Average3: 0.62
200-Day Moving Average3: 0.79
Share Statistics
Avg Vol (3 month)3: 126,551
Avg Vol (10 day)3: 85,925
Shares Outstanding5: 20.70M
Float: 8.41M
% Held by Insiders1: 18.61%
% Held by Institutions1: 12.60%
Shares Short (as of Apr 15, 2016)3: 377.32K
Short Ratio (as of Apr 15, 2016)3: 1.92
Short % of Float (as of Apr 15, 2016)3: 3.31%
Shares Short (prior month)3: 435.66K
https://finance.yahoo.com/q/ks?s=TBIO+Key+Statistics
Major Holders: https://finance.yahoo.com/q/mh?s=TBIO+Major+Holders
Profile
Transgenomic Inc.
12325 Emmet Street
Omaha, NE 68164
United States - Map
Phone: 402-452-5400
Fax: 402-452-5401
Website: http://www.transgenomic.com
Details
Index Membership: N/A
Sector: Technology
Industry: Scientific & Technical Instruments
Full Time Employees: 150
Business Summary
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States. The company provides genetic analytical laboratory services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. It employs various genomic testing service technologies, including ICE COLD-PCR, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The company was founded in 1997 and is headquartered in Omaha, Nebraska.
https://finance.yahoo.com/q/pr?s=TBIO+Profile
Chart: http://stockcharts.com/h-sc/ui?s=tbio